Undisclosed BCMA/GPRC5D dual-targeting CAR-T
/ Miltenyi Biotec, Miltenyi Biomedicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
Novel BCMA/GPRC5D dual-targeting CAR-T cells mitigate antigen escape with a favorable safety profile for multiple myeloma
(SITC 2026)
- No abstract available
CAR T-Cell Therapy • Clinical • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1